Handelsavisen
prelaunch
Companies Healthcare MABP.WA
MA
MABP.WA Warsaw Stock Exchange Biotechnology & Medical Research

Mabion SA

$0,39
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
18,7 %
ROE
-1,1 %
Net margin
-2,8 %
Debt / equity
0,30
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Mabion SA is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biopharmaceutical products.

Business. Mabion SA (MABP.WA) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-1,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning MABP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to MABP.WA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Mabion SA (MABP.WA) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Mabion SA maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.3, indicating a low reliance on debt financing. The company holds PLN 47.8 million in cash and equivalents, which is a significant portion of its total assets of PLN 208.3 million. However, its liquidity position is rated as low, and its operating cash flow is negative at PLN -2.3 million, suggesting potential challenges in maintaining short-term liquidity.

    Profitability metrics for Mabion are mixed. The company reported a gross profit of PLN 33.5 million on revenue of PLN 46.5 million, yielding a gross margin of 72.1%. However, net income was negative at PLN -1.3 million, and return on equity (ROE) was -1.1%, indicating poor capital efficiency. These figures fall below the industry median for ROE and ROA, which are typically positive for biotechnology firms, suggesting underperformance relative to peers.

    Mabion's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or product concentration risk. The company's exposure to specific markets or product lines remains opaque, and no material revenue concentration is disclosed.

    The company's growth trajectory is uncertain. While revenue increased to PLN 46.5 million in the latest period, the net loss and negative operating cash flow suggest operational inefficiencies. Analysts reported a last actual revenue of PLN 69.0 million, which may indicate a discrepancy or a reporting period mismatch. The outlook for the current and next fiscal years is not explicitly provided, but the negative free cash flow of PLN -18.6 million and capital expenditure of PLN -38.0 million suggest a capital-intensive growth strategy.

    Risk factors for Mabion include its low liquidity and the potential for dilution, although the risk of dilution is currently rated as low. The company has not issued additional shares recently, and no immediate filing-based liquidity or dilution flags were detected. However, the negative net income and operating cash flow could signal underlying financial stress.

    Recent events include the latest financial filing, which shows a net loss and negative operating cash flow. No significant regulatory or market events were disclosed in the available data. The company's capital expenditure of PLN -38.0 million indicates ongoing investment in infrastructure or R&D, but the source of funding for these expenditures is not specified.

    Key takeaways
    • Mabion SA has a low debt-to-equity ratio of 0.3, indicating a conservative capital structure.
    • The company reported a negative net income of PLN -1.3 million and a return on equity of -1.1%, suggesting poor profitability.
    • Mabion's liquidity position is rated as low, with a negative operating cash flow of PLN -2.3 million.
    • The company's capital expenditure of PLN -38.0 million indicates ongoing investment, but the source of funding is unclear.
    • No immediate filing-based liquidity or dilution flags were detected, suggesting a relatively stable capital structure.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 2

    The company's cash conversion ratio of 1.79 is best-in-class compared to the cohort median of 0.87.

    Low dilution, liquidity, and credit risk flags suggest a stable financial structure despite recent operational volatility.

    BEAR CASE · 1

    Capital expenditure relative to revenue is in the bottom quartile of the cohort, potentially limiting future growth capacity.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2024-10-29
    Q3 2024 · Quarter highlights

    Revenue PLN 516.0k; Operating income -PLN 15.1M.

    RevenuePLN 516.0k
    Operating income-PLN 15.1M
    Net income-PLN 16.3M
    Free cash flow-PLN 15.1M
    EPS
    Operating cash flowPLN 48.1M
    Financials
    Income statement
    RevenuePLN 516.0k
    Gross profitPLN 398.0k
    Operating income-PLN 15.1M
    Net income-PLN 16.3M
    Margins
    Gross margin77.1%
    Operating margin-2930.4%
    Net margin-3157.4%
    FCF margin-2927.5%
    Balance sheet
    Total assetsPLN 179.3M
    Total liabilitiesPLN 50.0M
    Total equityPLN 129.3M
    Cash & equivalentsPLN 47.0M
    Long-term debtPLN 3.7M
    Cash flow
    Operating cash flowPLN 48.1M
    CapEx-PLN 12.3M
    Free cash flow-PLN 15.1M
    SBC
    P&L flow · revenue → net income
    Revenue PLN 516.0kOperating costs PLN 15.6MTax PLN 1.2MNet income PLN 16.3M
    Highlights
    • Revenue PLN 516.0k
    • Operating income -PLN 15.1M
    • Net margin -3157.4%

    Valuation TTM

    Market price
    $0,39
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $117.8M
    Net cash
    $12.0M
    Current ratio
    1.6
    Debt / equity
    0.3
    ROA
    -0.6%
    ROE
    -1.1%
    Cash conversion
    179.0%
    CapEx / revenue
    -81.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin18,7 %Above P75
    Net Margin-2,8 %Above median
    ROE-1,1 %Above median
    Capex / Rev-81,7 %Bottom quartile
    D/E0,30Bottom quartile
    Cash Conv1,79Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Mabion SA Market data — financials · 2026-05-28
    • Mabion SA Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Leadership

    • Grzegorz GrabowiczMember of the Management Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    MABP.WACanonical
    Warsaw Stock Exchange · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2025-04-24 09:21 UTCEARNINGSAnnual results — FY 2025 Revenue PLN 69.0M · Net PLN -6.3M
    2024-10-29 05:53 UTCEARNINGSQuarterly results — Q3 2024 Revenue PLN 0.5M · Net PLN -16.3M
    2024-09-10 13:09 UTCEARNINGSQuarterly results — Q2 2024 Revenue PLN 29.8M · Net PLN 10.3M
    2024-05-14 13:54 UTCEARNINGSQuarterly results — Q1 2024 Revenue PLN 34.0M · Net PLN 17.5M
    2024-04-16 19:59 UTCEARNINGSQuarterly results — Q1 2024 Revenue PLN 46.5M · Net PLN -1.3M
    2024-04-16 19:59 UTCEARNINGSAnnual results — FY 2024 Revenue PLN 151.7M · Net PLN 41.3M
    2023-04-22 14:44 UTCEARNINGSAnnual results — FY 2023 Revenue PLN 164.0M · Net PLN 23.2M
    2022-04-22 07:12 UTCEARNINGSAnnual results — FY 2022 Revenue PLN 56.9M · Net PLN 1.9M
    2021-05-04 07:21 UTCEARNINGSAnnual results — FY 2021 Revenue PLN 0.0M · Net PLN -55.8M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage